{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:32:46Z","timestamp":1784608366244,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41375-025-02857-3","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T10:55:24Z","timestamp":1768215324000},"page":"502-510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8532-544X","authenticated-orcid":false,"given":"Rohtesh S.","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1649-7651","authenticated-orcid":false,"given":"Yosra M.","family":"Aljawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-9404","authenticated-orcid":false,"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Rondon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Fingrut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5524-5077","authenticated-orcid":false,"given":"Portia","family":"Smallbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1264-5968","authenticated-orcid":false,"given":"Betul","family":"Oran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1669-0355","authenticated-orcid":false,"given":"Amanda","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-5037","authenticated-orcid":false,"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"2857_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","volume":"31","author":"SR Spellman","year":"2025","unstructured":"Spellman SR, Xu K, Oloyede T, Ahn KW, Akhtar O, Bolon YT, et al. Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy\u2014a report from the CIBMTR. Transplant Cell Ther. 2025;31:505\u201332.","journal-title":"Transplant Cell Ther"},{"key":"2857_CR2","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bolanos-Meade","year":"2023","unstructured":"Bolanos-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338\u201348.","journal-title":"N Engl J Med"},{"key":"2857_CR3","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1182\/bloodadvances.2025016236","volume":"9","author":"YM Aljawai","year":"2025","unstructured":"Aljawai YM, Ramdial J, Rondon G, Smallbone P, Kebriaei P, Popat U, et al. Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis. Blood Adv. 2025;9:4023\u201336.","journal-title":"Blood Adv"},{"key":"2857_CR4","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/ajh.27648","volume":"100","author":"RS Mehta","year":"2025","unstructured":"Mehta RS, Sparapani R, Wang T, Spellman S, Lee SJ, Petersdorf EW. Donor age matters for haploidentical HCT patients even after adjusting for HLA factors: a machine learning approach. Am J Hematol. 2025;100:937\u201340.","journal-title":"Am J Hematol"},{"key":"2857_CR5","doi-asserted-by":"publisher","unstructured":"Mehta RS, Schmidt G, Williams K, Patel SA, Schetelig J, Savani B, et al. Choosing between HLA-mismatched unrelated and haploidentical donors: donor age considerations. Transplant Cell Ther. 2025; https:\/\/doi.org\/10.1016\/j.jtct.2025.05.019.","DOI":"10.1016\/j.jtct.2025.05.019"},{"key":"2857_CR6","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1038\/s41409-024-02400-5","volume":"59","author":"A Nagler","year":"2024","unstructured":"Nagler A, Labopin M, Swoboda R, Blaise D, Angelucci E, Vydra J, et al. Young (<35 years) haploidentical versus old (>\/=35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2024;59:1552\u201362.","journal-title":"Bone Marrow Transplant"},{"key":"2857_CR7","doi-asserted-by":"publisher","unstructured":"Aljawai YM, Ramdial JL, Rondon G, Smallbone P, Kebriaei P, Popat UR, et al. Outcomes of haploidentical vs mismatched unrelated donor HCT with post-transplant cyclophosphamide prophylaxis. Blood Adv. 2025; https:\/\/doi.org\/10.1182\/bloodadvances.2025016236.","DOI":"10.1182\/bloodadvances.2025016236"},{"key":"2857_CR8","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1182\/bloodadvances.2020003922","volume":"5","author":"AE DeZern","year":"2021","unstructured":"DeZern AE, Franklin C, Tsai HL, Imus PH, Cooke KR, Varadhan R, et al. Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2021;5:1360\u20138.","journal-title":"Blood Adv"},{"key":"2857_CR9","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/bloodadvances.2023012133","volume":"8","author":"J Sanz","year":"2024","unstructured":"Sanz J, Labopin M, Blaise D, Raiola AM, Busca A, Vydra J, et al. Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT. Blood Adv. 2024;8:2332\u201341.","journal-title":"Blood Adv"},{"key":"2857_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/ajh.27126","volume":"99","author":"RM Saliba","year":"2024","unstructured":"Saliba RM, Kanakry CG, Gadalla S, Kebriaei P, Rezvani K, Champlin RE, et al. Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age. Am J Hematol. 2024;99:38\u201347.","journal-title":"Am J Hematol"},{"key":"2857_CR11","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1182\/bloodadvances.2017014829","volume":"2","author":"SR McCurdy","year":"2018","unstructured":"McCurdy SR, Zhang MJ, St Martin A, Al Malki MM, Bashey A, Gaballa S, et al. Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide. Blood Adv. 2018;2:299\u2013307.","journal-title":"Blood Adv"},{"key":"2857_CR12","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1182\/blood.2021013443","volume":"139","author":"EJ Fuchs","year":"2022","unstructured":"Fuchs EJ, McCurdy SR, Solomon SR, Wang T, Herr MM, Modi D, et al. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood. 2022;139:1452\u201368.","journal-title":"Blood"},{"key":"2857_CR13","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1182\/bloodadvances.2024012669","volume":"8","author":"RS Mehta","year":"2024","unstructured":"Mehta RS, Petersdorf EW, Spellman SR, Lee SJ. Combined effect of unrelated donor age and HLA peptide-binding motif match status on HCT outcomes. Blood Adv. 2024;8:2235\u201342.","journal-title":"Blood Adv"},{"key":"2857_CR14","doi-asserted-by":"publisher","first-page":"909 e1","DOI":"10.1016\/j.jtct.2024.07.005","volume":"30","author":"RS Mehta","year":"2024","unstructured":"Mehta RS, Petersdorf EW, Wang T, Lee SJ. Haploidentical versus mismatched unrelated donor hematopoietic cell transplantation: HLA factors and donor age considerations. Transplant Cell Ther. 2024;30:909 e1\u2013909 e11.","journal-title":"Transplant Cell Ther"},{"key":"2857_CR15","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/ajh.24963","volume":"93","author":"J Canaani","year":"2018","unstructured":"Canaani J, Savani BN, Labopin M, Huang XJ, Ciceri F, Arcese W, et al. Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. Am J Hematol. 2018;93:246\u201353.","journal-title":"Am J Hematol"},{"key":"2857_CR16","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1182\/blood-2015-08-663823","volume":"127","author":"C Kollman","year":"2016","unstructured":"Kollman C, Spellman SR, Zhang MJ, Hassebroek A, Anasetti C, Antin JH, et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016;127:260\u20137.","journal-title":"Blood"},{"key":"2857_CR17","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.bbmt.2018.02.006","volume":"24","author":"BE Shaw","year":"2018","unstructured":"Shaw BE, Logan BR, Spellman SR, Marsh SGE, Robinson J, Pidala J, et al. Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most. Biol Blood Marrow Transpl. 2018;24:1049\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2857_CR18","first-page":"494","volume":"5","author":"BR Logan","year":"2021","unstructured":"Logan BR, Maiers MJ, Sparapani RA, Laud PW, Spellman SR, McCulloch RE, et al. Optimal donor selection for hematopoietic cell transplantation using Bayesian machine learning. JCO Clin Cancer Inf. 2021;5:494\u2013507.","journal-title":"JCO Clin Cancer Inf"},{"key":"2857_CR19","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1182\/bloodadvances.2024013756","volume":"8","author":"SR Spellman","year":"2024","unstructured":"Spellman SR, Sparapani R, Maiers M, Shaw BE, Laud P, Bupp C, et al. Novel machine learning technique further clarifies unrelated donor selection to optimize transplantation outcomes. Blood Adv. 2024;8:6082\u20137.","journal-title":"Blood Adv"},{"key":"2857_CR20","doi-asserted-by":"publisher","unstructured":"Mehta RS, Aljawai YM, Kebriaei P, Olson A, Oran B, Rondon G, et al. The impact of isolated hla-dqb1 mismatch and donor age in unrelated donor hematopoietic cell transplantation with post-transplant cyclophosphamide. Transplant Cell Ther. 2025; https:\/\/doi.org\/10.1016\/j.jtct.2025.08.011.","DOI":"10.1016\/j.jtct.2025.08.011"},{"key":"2857_CR21","doi-asserted-by":"publisher","first-page":"672 e1","DOI":"10.1016\/j.jtct.2025.05.005","volume":"31","author":"RS Mehta","year":"2025","unstructured":"Mehta RS, Aljawai YM, Al-Juhaishi T, Saultz J, Milano F, Kanakry JA, et al. Role of donor cytomegalovirus serostatus in cytomegalovirus-seronegative recipients of unrelated donor hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis. Transplant Cell Ther. 2025;31:672 e1\u2013672 e9.","journal-title":"Transplant Cell Ther"},{"key":"2857_CR22","doi-asserted-by":"publisher","unstructured":"Mehta RS, Sparapani RA, Kanakry CG, McCurdy SR, Saultz J, Lazaryan A, et al. Unrelated donor age and recipient outcomes after posttransplant cyclophosphamide vs conventional prophylaxis. JAMA Oncol. 2025; https:\/\/doi.org\/10.1001\/jamaoncol.2025.4551.","DOI":"10.1001\/jamaoncol.2025.4551"},{"key":"2857_CR23","doi-asserted-by":"crossref","unstructured":"Devine S, Astha V, Kuxhausen M, Bupp C, Stefanski H, Shaw B, et al. The 51st annual meeting of the European society for blood and marrow transplantation: physicians - oral session (O008-O166). Bone Marrow Transplant 2025;60:19\u2013182.","DOI":"10.1038\/s41409-025-02650-x"},{"key":"2857_CR24","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1182\/bloodadvances.2024014858","volume":"9","author":"K Nath","year":"2025","unstructured":"Nath K, Zhang MJ, Bye M, Abid MB, Benjamin C, Betts B, et al. Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis. Blood Adv. 2025;9:3469\u201378.","journal-title":"Blood Adv"},{"key":"2857_CR25","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/s41375-024-02256-0","volume":"38","author":"J Ramdial","year":"2024","unstructured":"Ramdial J, Kebriaei P, Champlin RE, Popat U, Rezvani K, Shpall EJ, et al. Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis. Leukemia. 2024;38:1432\u20134.","journal-title":"Leukemia"},{"key":"2857_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1182\/blood.2021011281","volume":"138","author":"M Gooptu","year":"2021","unstructured":"Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, et al. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021;138:273\u201382.","journal-title":"Blood"},{"key":"2857_CR27","doi-asserted-by":"publisher","first-page":"377.e1","DOI":"10.1016\/j.jtct.2023.03.028","volume":"29","author":"RS Mehta","year":"2023","unstructured":"Mehta RS, Ramdial J, Marin D, Alousi A, Kanakry CG, Champlin RE, et al. Impact of donor age in haploidentical-post-transplantation cyclophosphamide versus matched unrelated donor post-transplantation cyclophosphamide hematopoietic stem cell transplantation in patients with acute myeloid leukemia. Transplant Cell Ther. 2023;29:377.e1\u2013377.e7.","journal-title":"Transplant Cell Ther"},{"key":"2857_CR28","doi-asserted-by":"publisher","first-page":"395 e1","DOI":"10.1016\/j.jtct.2022.04.020","volume":"28","author":"RS Mehta","year":"2022","unstructured":"Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, et al. Haploidentical versus matched unrelated versus matched sibling donor hematopoietic cell transplantation with post-transplantation cyclophosphamide. Transplant Cell Ther. 2022;28:395 e1\u2013395 e11. Jul.","journal-title":"Transplant Cell Ther"},{"key":"2857_CR29","doi-asserted-by":"publisher","unstructured":"Modi D, Aljawai YM, DeFor TE, Bupp C, Al Malki MM, Bolanos-Meade J, et al. Matched unrelated vs haploidentical donor hematopoietic cell transplantation using post-transplant cyclophosphamide. Blood Adv. 2025; https:\/\/doi.org\/10.1182\/bloodadvances.2025017194.","DOI":"10.1182\/bloodadvances.2025017194"},{"key":"2857_CR30","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1182\/bloodadvances.2022007741","volume":"6","author":"A Ambinder","year":"2022","unstructured":"Ambinder A, Jain T, Tsai HL, Horowitz MM, Jones RJ, Varadhan R. HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age. Blood Adv. 2022;6:4335\u201346.","journal-title":"Blood Adv"},{"key":"2857_CR31","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1182\/bloodadvances.2024013853","volume":"8","author":"RS Mehta","year":"2024","unstructured":"Mehta RS, Ramdial J, Kebriaei P, Champlin RE, Popat U, Rezvani K, et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 2024;8:5306\u201314.","journal-title":"Blood Adv"},{"key":"2857_CR32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S1470-2045(12)70004-9","volume":"13","author":"K Fleischhauer","year":"2012","unstructured":"Fleischhauer K, Shaw BE, Gooley T, Malkki M, Bardy P, Bignon JD, et al. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol. 2012;13:366\u201374.","journal-title":"Lancet Oncol"},{"key":"2857_CR33","doi-asserted-by":"crossref","unstructured":"Dehn JG, Logan B, Shaw BE, Devine S, Ciurea SO, Horowitz M, et al. Access to allogeneic cell transplantation based on donor search prognosis: an interventional trial. medRxiv. 2024.","DOI":"10.1101\/2024.09.16.24313494"},{"key":"2857_CR34","doi-asserted-by":"crossref","unstructured":"Lee SJ, Logan BR, Horowitz MM, Westervelt P, Hogan WJ, Pidala JA, et al. Likelihood of finding an 8\/8 HLA-matched unrelated donor (Donor Search Prognosis) is not associated with survival: Primary results from BMT CTN 1702. Blood. 2024;144:695.","DOI":"10.1182\/blood-2024-200833"},{"key":"2857_CR35","doi-asserted-by":"publisher","first-page":"917 e1","DOI":"10.1016\/j.jtct.2024.06.021","volume":"30","author":"R Cusatis","year":"2024","unstructured":"Cusatis R, Litovich C, Feng Z, Allbee-Johnson M, Kapfhammer M, Mattila D, et al. Current Trends and outcomes in cellular therapy activity in the United States, including prospective patient-reported outcomes data collection in the Center for International Blood and Marrow Transplant Research Registry. Transplant Cell Ther. 2024;30:917 e1\u2013917 e12.","journal-title":"Transplant Cell Ther"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02857-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02857-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02857-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T07:38:12Z","timestamp":1772609892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02857-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2857"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02857-3","relation":{"is-basis-for":[{"id-type":"doi","id":"10.52843\/cassyni.hnl3h9","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"11 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RSM served as a consultant reviewer for OrcaBio and received honorarium from Lumanity for providing Expert Opinion. EJS serves as a consultant for Cimeio Therapeutics AG, New York Blood Center, Celaid Therapeutics Inc, Scientific Advisor for Adaptimmune Limited, Navan Technologie, Axio Research, FibroBiologics, is on the Board of Directors\/Management for National Marrow Donor Program, and License agreement for Affimed, Takeda, Rege Nexus, and is a speaker for Dava Oncology. The University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Takeda Pharmaceutical and Affimed GmbH.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by our Institutional Review Board (2025-0916) which granted a Waiver of HIPAA Authorization for this non-interventional, retrospective research, and adhered to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}